NewAmsterdam Pharma (NAMS) Net Income towards Common Stockholders (2023 - 2025)
Historic Net Income towards Common Stockholders for NewAmsterdam Pharma (NAMS) over the last 3 years, with Q3 2025 value amounting to -$72.0 million.
- NewAmsterdam Pharma's Net Income towards Common Stockholders fell 33254.04% to -$72.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$221.1 million, marking a year-over-year decrease of 1115.4%. This contributed to the annual value of -$241.6 million for FY2024, which is 3654.46% down from last year.
- As of Q3 2025, NewAmsterdam Pharma's Net Income towards Common Stockholders stood at -$72.0 million, which was down 33254.04% from -$17.4 million recorded in Q2 2025.
- NewAmsterdam Pharma's 5-year Net Income towards Common Stockholders high stood at -$16.6 million for Q3 2024, and its period low was -$93.8 million during Q1 2024.
- For the 3-year period, NewAmsterdam Pharma's Net Income towards Common Stockholders averaged around -$50.9 million, with its median value being -$44.6 million (2023).
- As far as peak fluctuations go, NewAmsterdam Pharma's Net Income towards Common Stockholders skyrocketed by 6468.08% in 2024, and later plummeted by 33254.04% in 2025.
- Quarter analysis of 3 years shows NewAmsterdam Pharma's Net Income towards Common Stockholders stood at -$49.5 million in 2023, then plummeted by 86.34% to -$92.2 million in 2024, then increased by 21.88% to -$72.0 million in 2025.
- Its last three reported values are -$72.0 million in Q3 2025, -$17.4 million for Q2 2025, and -$39.5 million during Q1 2025.